Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 139

Modulating the DIPG microenvironment with virus and complement inhibitors as ...

Diffuse intrinsic pontine glioma (DIPG) is one of the most formidable challenges faced by pediatric oncologists. For the last 30 years, all treatment approaches for these type of tumors have failed, leaving a terrible prospect of survival at 5 years for these children virtually of zero. Thus, it is clear that new ...

Targeting a novel mitochondrial apoptotic pathway in Neuroblastoma

Mitochondria are subcellular, double-membrane organelles. From a functional point of view they can be considered as hubs where cellular energy metabolism and cell death signalling converge and are finely regulated. Functional mitochondria are essential for cancer cells. Many of the agents with anti-cancer activity that act on Mitochondria (Mi), hold ...

Testing cytotoxic effects and deciphering signalling pathways engaged by a ...

Glioblastoma (GBM) is the most common malignant brain tumor, being highly invasive and not responsive to standard treatment (surgery, radiotherapy, and chemotherapy). Moreover, a major determinant of the high lethality of GBM is the presence of self-renewing, tumorigenic glioblastoma stem-like cells (GSCs) that threateningly support the development and the progressive ...

MiR181 as novel biomarkers in precision medicine of Bile Duct ...

Bile Tract Cancers (BTC) include cholangiocarcinoma (CCA) and gallbladder cancer (GBC) and their incidence is increasing worldwide [1, 2] . Lack of effective radical treatments highlights the need for a better understanding of BTC biology and mechanisms of response to treatment [1, 2]. Eighty-percent of BTC patients present at an advanced stage, when treatment options ...

Unlocking the translational potential of the DIPG epigenome for a ...

Diffuse intrinsic pontine glioma (DIPG) is a malignant pediatric brain tumor with a very poor outlook, with an expected survival of one year. Lack of access to biological tissue sample continues to be the largest barrier to advancing treatment. In 2016, the World Health Organization (WHO) reclassified DIPG tumors as diffuse ...